JP2001520042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001520042A5 JP2001520042A5 JP2000517087A JP2000517087A JP2001520042A5 JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5 JP 2000517087 A JP2000517087 A JP 2000517087A JP 2000517087 A JP2000517087 A JP 2000517087A JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- vitamin
- gla domain
- dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 150000001413 amino acids Chemical group 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 229930003448 Vitamin K Natural products 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 22
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 22
- 235000019168 vitamin K Nutrition 0.000 description 22
- 239000011712 vitamin K Substances 0.000 description 22
- 150000003721 vitamin K derivatives Chemical class 0.000 description 22
- 229940046010 vitamin k Drugs 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
| US08/955,636 | 1997-10-23 | ||
| PCT/US1998/022152 WO1999020767A1 (en) | 1997-10-23 | 1998-10-20 | Modified vitamin k-dependent polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001520042A JP2001520042A (ja) | 2001-10-30 |
| JP2001520042A5 true JP2001520042A5 (https=) | 2006-01-05 |
| JP4276379B2 JP4276379B2 (ja) | 2009-06-10 |
Family
ID=25497114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000517087A Expired - Fee Related JP4276379B2 (ja) | 1997-10-23 | 1998-10-20 | 改変型ビタミンｋ依存性ポリペプチド |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (https=) |
| EP (2) | EP1090128B1 (https=) |
| JP (1) | JP4276379B2 (https=) |
| KR (1) | KR20010031370A (https=) |
| CN (1) | CN1246462C (https=) |
| AP (1) | AP2000001811A0 (https=) |
| AR (2) | AR020048A1 (https=) |
| AT (1) | ATE390486T1 (https=) |
| AU (1) | AU749279C (https=) |
| BR (1) | BR9814611A (https=) |
| CA (1) | CA2307175C (https=) |
| DE (1) | DE69839313T2 (https=) |
| DK (1) | DK1090128T3 (https=) |
| EA (1) | EA200000449A1 (https=) |
| ES (2) | ES2303362T3 (https=) |
| HR (1) | HRP20000234A2 (https=) |
| HU (1) | HU225993B1 (https=) |
| ID (1) | ID26330A (https=) |
| IL (1) | IL135603A0 (https=) |
| IS (1) | IS5449A (https=) |
| MY (1) | MY136336A (https=) |
| NO (1) | NO20002025L (https=) |
| NZ (1) | NZ504114A (https=) |
| PL (1) | PL194194B1 (https=) |
| PT (1) | PT1090128E (https=) |
| SG (1) | SG105547A1 (https=) |
| TR (1) | TR200001105T2 (https=) |
| TW (1) | TW587081B (https=) |
| WO (1) | WO1999020767A1 (https=) |
| ZA (1) | ZA989597B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| WO2001036462A2 (en) * | 1999-11-19 | 2001-05-25 | Eli Lilly And Company | Protein c derivatives |
| WO2001057193A2 (en) | 2000-02-02 | 2001-08-09 | Eli Lilly And Company | Protein c derivatives |
| CA2739933A1 (en) | 2000-02-11 | 2001-08-16 | Bayer Healthcare Llc | Factor vii or viia-like molecules |
| CA2400187A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| JP2004505035A (ja) * | 2000-07-31 | 2004-02-19 | オタワ・ハート・インスティテュート・リサーチ・コーポレーション | 荷電脂質組成物及びその使用方法 |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| AU2002235073B2 (en) * | 2001-03-02 | 2007-02-01 | T.A.C. Thrombosis And Coagulation Ab | Protein C variants |
| US20050176083A1 (en) * | 2002-03-01 | 2005-08-11 | Bjorn Dahlback | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| WO2003093465A1 (en) * | 2002-04-30 | 2003-11-13 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| CN1671410B (zh) | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的稳定化固体组合物 |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| CN101818137A (zh) | 2003-03-18 | 2010-09-01 | 诺和诺德医疗保健公司 | 生产含有gla残基的丝氨酸蛋白酶的方法 |
| CA2519873C (en) * | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
| RU2373282C2 (ru) * | 2003-06-19 | 2009-11-20 | Байер Хелткэр Ллк | ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa |
| ES2381110T3 (es) | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| JP4874806B2 (ja) | 2003-12-01 | 2012-02-15 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 液体因子ｖｉｉ組成物のウイルス濾過 |
| CN1917861B (zh) | 2003-12-19 | 2012-03-21 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| EP2360171A1 (en) | 2004-12-23 | 2011-08-24 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| WO2007006808A1 (en) | 2005-07-13 | 2007-01-18 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
| JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| WO2008025856A2 (en) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| JP2010513462A (ja) * | 2006-12-20 | 2010-04-30 | バイエル・ヘルスケア・エルエルシー | 第ＶＩＩおよび第ＶＩＩａ因子組成物 |
| CA2683443A1 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| SG187397A1 (en) | 2007-12-27 | 2013-02-28 | Baxter Int | Cell culture processes |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| NO2440239T3 (https=) | 2009-06-09 | 2018-02-10 | ||
| JP5818319B2 (ja) * | 2009-12-14 | 2015-11-18 | 国立大学法人北海道大学 | 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296413A2 (en) * | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001520042A5 (https=) | ||
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| Sadler | Thrombomodulin structure and function | |
| Kato et al. | Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme | |
| TW585871B (en) | Improved methods for processing activated protein C | |
| Clark et al. | Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phosoholipase C in mammalian cells | |
| WO2001045746A3 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
| JP2799316B2 (ja) | 雑種ヒトプロテインｃおよびその遺伝子工学的製法 | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| JP2002513556A5 (https=) | ||
| KR20160008521A (ko) | 콜레스테롤 수준을 변경하는 조성물 및 방법 | |
| JP2014094009A (ja) | 改変型ビタミンｋ依存性ポリペプチド | |
| CA2674879A1 (en) | Improved fix-mutant proteins for hemophilia b treatment | |
| KR910003094A (ko) | 흡혈박쥐속(Vampire bat) 타액 플라스미노겐 활성인자 | |
| CA2563675A1 (en) | Recombinantly modified plasmin | |
| Orawski et al. | Purification and properties of membrane-bound aminopeptidase P from rat lung | |
| US20240352090A1 (en) | Use of protein sequence capable of binding to substrate in preparation of product for inhibiting fibrin assembly | |
| AU2444795A (en) | A process for separating milk clotting enzymes, and stable rennet compositions | |
| Friedman et al. | Vitamin K-dependent carboxylation | |
| SK22695A3 (en) | Isolation and purification method of proteins dependent from vitamin k | |
| CA2002833A1 (en) | Interferon-gamma binding proteins | |
| JP7843331B2 (ja) | 第ｘａ因子及び誘導体を調製するための組成物及び方法 | |
| CA1258242A (en) | Urokinase zymogen and composition containing the same | |
| Noda et al. | Activation of immobilized, biotinylated choleragen A1 protein by a 19-kilodalton guanine nucleotide-binding protein | |
| Vatandoost et al. | Effect of propeptide amino acid substitution in γ‐carboxylation, activity and expression of recombinant human coagulation factor IX |